A Comparison Of The Hemolytic Potential Of Optison™ And Albunex® In Whole Human Blood In Vitro: Acoustic Pressure, Ultrasound Frequency, Donor And Passive Cavitation Detection Considerations
Ultrasound In Medicine And Biology
This project tested the hypothesis that a "second-generation'' ultrasound (US) contrast agent (Optison((TM))), offering extended echogenicity over that of its "first-generation" predecessor (Albunex((R))), would have the greater potential for sonolysis of human erythrocytes in vitro, Whole human blood, obtained from apparently healthy donors, was anticoagulated and subsequently exposed irt vitro to US in the presence of one of each or neither of the two US contrast agents. The US exposures were for 30 s and involved frequency (1.0, 2.2 and 3.4 MHz) and amplitude (similar to2.8 to 0.38 mPa P-) regimens; pulse duration (200 mus) and interpulse interval (20 ms) were held constant, The data supported the hypothesis, with an overall ratio of similar to2.5 for relative extent of background-corrected US-induced hemolysis of the Optison((TM))/Albunex((R)) regimens. Passive cavitation detection analyses corroborated the results obtained with hemolysis, (E-mail: email@example.com) (C) 2001 World Federation for Ultrasound in Medicine & Biology.
M. W. Miller, E. Carr Everbach, C. Cox, R. R. Knapp, A. A. Brayman, and T. A. Sherman.
"A Comparison Of The Hemolytic Potential Of Optison™ And Albunex® In Whole Human Blood In Vitro: Acoustic Pressure, Ultrasound Frequency, Donor And Passive Cavitation Detection Considerations".
Ultrasound In Medicine And Biology.
This document is currently not available here.